5. Delcath Systems ( DCTH) is a development-stage company that has developed a system to administer chemotherapy and other therapeutic agents.
For 2010 fourth quarter, analysts polled by Bloomberg expect the company to report a loss of 17 cents per share, compared to a loss of 18 cents per share and a loss of 24 cents per share in the year-ago and quarter-ago periods, respectively. Delcath is anticipated to turn profitable during the September quarter of 2012. The stock surged around 104% during the past one year, while CareFusion ( CFN), Insulet ( PODD), ICU Medical ( ICUI) and AngioDynamics ( ANGO) posted returns of around -3%, 20%, 11% and -0.2%, respectively. All the five analysts covering the stock recommend buying and expect the stock to gain around 92% over the next 12 months with a consensus target price of $18.0.